Drug intelligence / Profile preview

KaB-103

Development stage: Preclinical
Lead developer: Kanpecia Biotech
Modality: Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Topical

Overview

KaB-103 is a preclinical-stage topical small molecule drug candidate being developed by Kanpecia Biotech for the treatment of chemotherapy-induced alopecia (CIA) and androgenic alopecia. Spun out of the University of Kansas, the drug utilizes a proprietary liposomal delivery system (referred to as Kanpecia Liposomal SPR4) designed for painless and easy scalp application. In rodent models, KaB-103 has demonstrated superior hair growth rates compared to minoxidil and has shown a favorable safety profile with no observed systemic toxicity. While the specific molecular target remains undisclosed, the drug is intended to provide a safe alternative to current treatments without systemic side effects.

Other names: Kanpecia Liposomal SPR4

Beyond the preview

Go deeper on KaB-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KaB-103.

Explore the full profile